AU2019210063B2 - Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same - Google Patents

Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same Download PDF

Info

Publication number
AU2019210063B2
AU2019210063B2 AU2019210063A AU2019210063A AU2019210063B2 AU 2019210063 B2 AU2019210063 B2 AU 2019210063B2 AU 2019210063 A AU2019210063 A AU 2019210063A AU 2019210063 A AU2019210063 A AU 2019210063A AU 2019210063 B2 AU2019210063 B2 AU 2019210063B2
Authority
AU
Australia
Prior art keywords
seq
fold
ltag
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019210063A
Other languages
English (en)
Other versions
AU2019210063A1 (en
Inventor
Elizabeth DUPERRET
David B. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of AU2019210063A1 publication Critical patent/AU2019210063A1/en
Application granted granted Critical
Publication of AU2019210063B2 publication Critical patent/AU2019210063B2/en
Priority to AU2025204247A priority Critical patent/AU2025204247A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019210063A 2018-01-19 2019-01-18 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same Active AU2019210063B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204247A AU2025204247A1 (en) 2018-01-19 2025-06-06 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619161P 2018-01-19 2018-01-19
US62/619,161 2018-01-19
PCT/US2019/014171 WO2019143921A2 (en) 2018-01-19 2019-01-18 Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204247A Division AU2025204247A1 (en) 2018-01-19 2025-06-06 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Publications (2)

Publication Number Publication Date
AU2019210063A1 AU2019210063A1 (en) 2020-08-20
AU2019210063B2 true AU2019210063B2 (en) 2025-03-06

Family

ID=67302504

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019210063A Active AU2019210063B2 (en) 2018-01-19 2019-01-18 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
AU2025204247A Pending AU2025204247A1 (en) 2018-01-19 2025-06-06 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204247A Pending AU2025204247A1 (en) 2018-01-19 2025-06-06 Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Country Status (11)

Country Link
US (2) US11524065B2 (enExample)
EP (1) EP3740226A4 (enExample)
JP (2) JP7485604B2 (enExample)
KR (1) KR20200110678A (enExample)
CN (2) CN120514835A (enExample)
AU (2) AU2019210063B2 (enExample)
BR (1) BR112020014632A2 (enExample)
CA (1) CA3088374A1 (enExample)
EA (1) EA202091732A1 (enExample)
MX (1) MX2020007676A (enExample)
WO (1) WO2019143921A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101134A1 (en) * 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) * 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028165A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101134A1 (en) * 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) * 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIANCA GOMEZ ET AL: "Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen", CELL & BIOSCIENCE, vol. 3, no. 1, 2013, pages 29 *
BIANCA P GOMEZ ET AL: "Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen", CELL & BIOSCIENCE, vol. 2, no. 1, 2012, pages 36 *

Also Published As

Publication number Publication date
US20200345830A1 (en) 2020-11-05
AU2025204247A1 (en) 2025-06-26
WO2019143921A3 (en) 2020-04-09
US20230201328A1 (en) 2023-06-29
CN111801111B (zh) 2025-06-10
CN120514835A (zh) 2025-08-22
KR20200110678A (ko) 2020-09-24
BR112020014632A2 (pt) 2021-01-05
CA3088374A1 (en) 2019-07-25
MX2020007676A (es) 2020-11-12
CN111801111A (zh) 2020-10-20
JP2024096334A (ja) 2024-07-12
EP3740226A2 (en) 2020-11-25
WO2019143921A2 (en) 2019-07-25
JP2021511320A (ja) 2021-05-06
JP7485604B2 (ja) 2024-05-16
US11524065B2 (en) 2022-12-13
EP3740226A4 (en) 2021-10-13
EA202091732A1 (ru) 2020-09-10
AU2019210063A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
WO2019161163A1 (en) Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
US12296001B2 (en) DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)
JP2024096334A (ja) メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法
US12390521B2 (en) Canine distemper vaccines and methods of treatment using the same
AU2018200638A1 (en) Immunotherapeutic composition, therapeutic method and diagnostic method
AU2017330338A1 (en) Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
US12268735B2 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US20250276051A1 (en) Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
WO2020041410A1 (en) Vaccines against nipah virus, and methods of using same
HK40038957A (en) Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
US12194000B2 (en) Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)
EA045600B1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения
HK40053340A (en) Vaccines against nipah virus, and methods of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)